SOAT1 and skin sarcoidosis: Studies on anti-JAK-STAT interventions demonstrate no adverse events after treatment; however, patient study size was limiting.Recent studies have shown promising potential for anti-TNF-α and anti-JAK-STAT inhibitors to become the mainstay interventions in refractory cutaneous sarcoidosis.